{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:03:48Z","timestamp":1790291028455,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Science and Technology Council, Taipei, Taiwan","award":["NSTC 113-2811-B-039-028 and NSTC 114-2811-B-008-002"],"award-info":[{"award-number":["NSTC 113-2811-B-039-028 and NSTC 114-2811-B-008-002"]}]},{"name":"National Science and Technology Council, Taipei, Taiwan","award":["NSTC 112-2314-B-758-001-MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-758-001-MY3"]}]},{"name":"National Science and Technology Council, Taipei, Taiwan","award":["NSTC 112-2314-B-039-063-MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-039-063-MY3"]}]},{"name":"Chang Bing Show Chwan Memorial Hospital, Changhua","award":["BRD-111014"],"award-info":[{"award-number":["BRD-111014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"DOI":"10.1186\/s10020-026-01432-5","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T04:05:43Z","timestamp":1771301143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fluoxetine suppresses triple-negative breast cancer progression by inducing apoptosis, inhibiting Src-mediated invasiveness, and enhancing anti-tumor immunity"],"prefix":"10.1186","volume":"32","author":[{"given":"Hsing-Ju","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueh-Shan","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Yi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Ting","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"1432_CR1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.6092\/1590-8577\/2638","volume":"15","author":"MG Binker","year":"2014","unstructured":"Binker MG, Binker-Cosen MJ, Binker-Cosen AA, Cosen-Binker LI. Microenvironmental factors and extracellular matrix degradation in pancreatic cancer. Jop. 2014;15:280\u20135. https:\/\/doi.org\/10.6092\/1590-8577\/2638.","journal-title":"Jop"},{"key":"1432_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0928-0","volume":"20","author":"J Busby","year":"2018","unstructured":"Busby J, Mills K, Zhang SD, Liberante FG, Cardwell CR. Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study. Breast Cancer Res. 2018;20:4. https:\/\/doi.org\/10.1186\/s13058-017-0928-0.","journal-title":"Breast Cancer Res"},{"key":"1432_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000504","volume":"4","author":"R Caparica","year":"2019","unstructured":"Caparica R, Lambertini M, de Azambuja E. How I treat metastatic triple-negative breast cancer. ESMO Open. 2019;4:e000504. https:\/\/doi.org\/10.1136\/esmoopen-2019-000504.","journal-title":"ESMO Open"},{"key":"1432_CR4","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/jcmm.13372","volume":"22","author":"VC Chen","year":"2018","unstructured":"Chen VC, Hsieh YH, Chen LJ, Hsu TC, Tzang BS. Escitalopram oxalate induces apoptosis in U-87MG cells and autophagy in GBM8401 cells. J Cell Mol Med. 2018;22:1167\u201378. https:\/\/doi.org\/10.1111\/jcmm.13372.","journal-title":"J Cell Mol Med"},{"key":"1432_CR5","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.21873\/anticanres.16265","volume":"43","author":"WT Chen","year":"2023","unstructured":"Chen WT, Tsai YH, Tan P, Hsu FT, Wang HD, Lin WC, Lin FH, Wu CT. Fluoxetine inhibits STAT3-mediated survival and invasion of osteosarcoma cells. Anticancer Res. 2023;43:1193\u20139. https:\/\/doi.org\/10.21873\/anticanres.16265.","journal-title":"Anticancer Res"},{"key":"1432_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112661","volume":"147","author":"IT Chiang","year":"2022","unstructured":"Chiang IT, Lee YH, Tan ZL, Hsu FT, Tu HF. Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma. Biomed Pharmacother. 2022;147:112661. https:\/\/doi.org\/10.1016\/j.biopha.2022.112661.","journal-title":"Biomed Pharmacother"},{"key":"1432_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10552-015-0689-y","volume":"27","author":"J Chubak","year":"2016","unstructured":"Chubak J, Bowles EJ, Yu O, Buist DS, Fujii M, Boudreau DM. Breast cancer recurrence in relation to antidepressant use. Cancer Causes Control. 2016;27:125\u201336. https:\/\/doi.org\/10.1007\/s10552-015-0689-y.","journal-title":"Cancer Causes Control"},{"key":"1432_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115663","volume":"168","author":"TG de Carvalho","year":"2023","unstructured":"de Carvalho TG, Lara P, Jorquera-Cordero C, Arag\u00e3o CFS, de Santana Oliveira A, Garcia VB, et al. Inhibition of murine colorectal cancer metastasis by targeting M2-TAM through STAT3\/NF-kB\/AKT signaling using macrophage 1-derived extracellular vesicles loaded with oxaliplatin, retinoic acid, and Libidibia ferrea. Biomed Pharmacother. 2023;168:115663. https:\/\/doi.org\/10.1016\/j.biopha.2023.115663.","journal-title":"Biomed Pharmacother"},{"key":"1432_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1105","volume":"1","author":"BS Dwarakanath","year":"2018","unstructured":"Dwarakanath BS, Farooque A, Gupta S. Targeting regulatory T cells for improving cancer therapy: challenges and prospects. Cancer Rep. 2018;1:e21105. https:\/\/doi.org\/10.1002\/cnr2.1105.","journal-title":"Cancer Rep"},{"key":"1432_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.tranon.2019.02.010","volume":"12","author":"P Economopoulou","year":"2019","unstructured":"Economopoulou P, Kotoula V, Koliou GA, Papadopoulou K, Christodoulou C, Pentheroudakis G, et al. Prognostic impact of Src, CDKN1B, and JAK2 expression in metastatic breast cancer patients treated with Trastuzumab. Transl Oncol. 2019;12:739\u201348. https:\/\/doi.org\/10.1016\/j.tranon.2019.02.010.","journal-title":"Transl Oncol"},{"key":"1432_CR11","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.21873\/anticanres.11611","volume":"37","author":"M Eskelinen","year":"2017","unstructured":"Eskelinen M, Selander T, Ollonen P, Korhonen R. Moderate\/severe depression (MADRS) can affect the quality of life and outcome among patients admitted to breast cancer diagnosis unit. Anticancer Res. 2017;37:2641\u20137. https:\/\/doi.org\/10.21873\/anticanres.11611.","journal-title":"Anticancer Res"},{"key":"1432_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/annonc\/mdx526","volume":"29","author":"L Grassi","year":"2018","unstructured":"Grassi L, Nanni MG, Rodin G, Li M, Caruso R. The use of antidepressants in oncology: a review and practical tips for oncologists. Ann Oncol. 2018;29:101\u201311. https:\/\/doi.org\/10.1093\/annonc\/mdx526.","journal-title":"Ann Oncol"},{"key":"1432_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0163-7258(99)00048-0","volume":"85","author":"C Hiemke","year":"2000","unstructured":"Hiemke C, H\u00e4rtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85:11\u201328. https:\/\/doi.org\/10.1016\/S0163-7258(99)00048-0.","journal-title":"Pharmacol Ther"},{"key":"1432_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061361","author":"PC Hsu","year":"2020","unstructured":"Hsu PC, Yang CT, Jablons DM, You L. The crosstalk between Src and Hippo\/YAP signaling pathways in non-small cell lung cancer (NSCLC). Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12061361.","journal-title":"Cancers (Basel)"},{"key":"1432_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081789","author":"FT Hsu","year":"2021","unstructured":"Hsu FT, Liu YC, Tsai CL, Yueh PF, Chang CH, Lan KL. Preclinical evaluation of recombinant human IL15 protein fused with albumin binding domain on anti-PD-L1 immunotherapy efficiency and anti-tumor immunity in colon cancer and melanoma. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13081789.","journal-title":"Cancers (Basel)"},{"key":"1432_CR16","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1111\/jcmm.17220","volume":"26","author":"FT Hsu","year":"2022","unstructured":"Hsu FT, Tsai CL, Chiang IT, Lan KH, Yueh PF, Liang WY, Lin CS, Chao Y, Lan KL. Synergistic effect of abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma. J Cell Mol Med. 2022;26:1955\u201368. https:\/\/doi.org\/10.1111\/jcmm.17220.","journal-title":"J Cell Mol Med"},{"key":"1432_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154947","volume":"119","author":"FT Hsu","year":"2023","unstructured":"Hsu FT, Liu WL, Lee SR, Jeng LB, Chen JH. Unveiling nature\u2019s potential weapon: Magnolol\u2019s role in combating bladder cancer by upregulating the miR-124 and inactivating PKC-\u03b4\/ERK axis. Phytomedicine. 2023;119:154947. https:\/\/doi.org\/10.1016\/j.phymed.2023.154947.","journal-title":"Phytomedicine"},{"key":"1432_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050885","author":"Q Huang","year":"2024","unstructured":"Huang Q, Wu M, Pu Y, Zhou J, Zhang Y, Li R, et al. Inhibition of TNBC cell growth by paroxetine: induction of apoptosis and blockage of autophagy flux. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16050885.","journal-title":"Cancers (Basel)"},{"key":"1432_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07860-2","volume":"21","author":"H Jiang","year":"2021","unstructured":"Jiang H, Li H. Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021;21:149. https:\/\/doi.org\/10.1186\/s12885-021-07860-2.","journal-title":"BMC Cancer"},{"key":"1432_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153705","volume":"95","author":"XL Jiang","year":"2022","unstructured":"Jiang XL, Deng B, Deng SH, Cai M, Ding WJ, Tan ZB, et al. Dihydrotanshinone I inhibits the growth of hepatoma cells by direct inhibition of Src. Phytomedicine. 2022;95:153705. https:\/\/doi.org\/10.1016\/j.phymed.2021.153705.","journal-title":"Phytomedicine"},{"key":"1432_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/jat\/31.7.409","volume":"31","author":"MD Johnson","year":"2007","unstructured":"Johnson MD, Lewis RJ, Angier MK. The distribution of fluoxetine and norfluoxetine in human tissues. J Anal Toxicol. 2007;31:409\u201314. https:\/\/doi.org\/10.1093\/jat\/31.7.409.","journal-title":"J Anal Toxicol"},{"key":"1432_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3857\/roj.2019.00640","volume":"38","author":"C Kang","year":"2020","unstructured":"Kang C, Jeong SY, Song SY, Choi EK. The emerging role of myeloid-derived suppressor cells in radiotherapy. Radiat Oncol J. 2020;38:1\u201310. https:\/\/doi.org\/10.3857\/roj.2019.00640.","journal-title":"Radiat Oncol J"},{"key":"1432_CR23","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.21873\/invivo.13177","volume":"37","author":"YC Li","year":"2023","unstructured":"Li YC, Wong CN, Hsu FT, Chen JH, Yang CC, Liu HH, Chen WL, Weng YS. Accessing apoptosis induction and metastasis inhibition effect of Magnolol on triple negative breast cancer in vitro. Vivo. 2023;37:1028\u201336. https:\/\/doi.org\/10.21873\/invivo.13177.","journal-title":"Vivo"},{"key":"1432_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.21873\/anticanres.16790","volume":"44","author":"CY Li","year":"2024","unstructured":"Li CY, Chen HC, Liao CY, Hsu FT, Hung KC, Liu KC, Chen JC, Ku MC. Lenvatinib suppresses protein kinase B signaling and induces apoptosis in osteosarcoma cells. Anticancer Res. 2024;44:85\u201392. https:\/\/doi.org\/10.21873\/anticanres.16790.","journal-title":"Anticancer Res"},{"key":"1432_CR25","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.21873\/anticanres.15871","volume":"42","author":"PA Liao","year":"2022","unstructured":"Liao PA, Chu PY, Tan ZL, Hsu FT, Lee YC, Wu HJ. STAT3 inactivation and induction of apoptosis associate with fluoxetine-inhibited epithelial-mesenchymal transition and growth of Triple-negative breast cancer in vivo. Anticancer Res. 2022;42:3807\u201314. https:\/\/doi.org\/10.21873\/anticanres.15871.","journal-title":"Anticancer Res"},{"key":"1432_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202105672","volume":"9","author":"Q Liu","year":"2022","unstructured":"Liu Q, Sun H, Liu Y, Li X, Xu B, Li L, et al. HTR1A inhibits the progression of Triple-Negative breast cancer via TGF-\u03b2 canonical and noncanonical pathways. Adv Sci. 2022;9:e2105672. https:\/\/doi.org\/10.1002\/advs.202105672.","journal-title":"Adv Sci"},{"key":"1432_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59071285","author":"J Liu","year":"2023","unstructured":"Liu J, Deng Y, Liu Z, Li X, Zhang M, Yu X, et al. Identification of genes associated with prognosis and immunotherapy prediction in triple-negative breast cancer via M1\/M2 macrophage ratio. Medicina Kaunas. 2023a. https:\/\/doi.org\/10.3390\/medicina59071285.","journal-title":"Medicina Kaunas"},{"key":"1432_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1199273","volume":"14","author":"H Liu","year":"2023","unstructured":"Liu H, Wang Z, Zhou Y, Yang Y. MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target. Front Immunol. 2023;14:1199273. https:\/\/doi.org\/10.3389\/fimmu.2023.1199273.","journal-title":"Front Immunol"},{"key":"1432_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101481","volume":"52","author":"AE Marciscano","year":"2021","unstructured":"Marciscano AE, Anandasabapathy N. The role of dendritic cells in cancer and anti-tumor immunity. Semin Immunol. 2021;52:101481. https:\/\/doi.org\/10.1016\/j.smim.2021.101481.","journal-title":"Semin Immunol"},{"key":"1432_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111077","volume":"133","author":"S Mirzaei","year":"2021","unstructured":"Mirzaei S, Gholami MH, Mahabady MK, Nabavi N, Zabolian A, Banihashemi SM, et al. Pre-clinical investigation of STAT3 pathway in bladder cancer: paving the way for clinical translation. Biomed Pharmacother. 2021;133:111077. https:\/\/doi.org\/10.1016\/j.biopha.2020.111077.","journal-title":"Biomed Pharmacother"},{"key":"1432_CR31","first-page":"3691","volume":"33","author":"AR Mun","year":"2013","unstructured":"Mun AR, Lee SJ, Kim GB, Kang HS, Kim JS, Kim SJ. Fluoxetine-induced apoptosis in hepatocellular carcinoma cells. Anticancer Res. 2013;33:3691\u20137.","journal-title":"Anticancer Res"},{"key":"1432_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030482","author":"EE Newton","year":"2022","unstructured":"Newton EE, Mueller LE, Treadwell SM, Morris CA, Machado HL. Molecular targets of triple-negative breast cancer: where do we stand? Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14030482.","journal-title":"Cancers (Basel)"},{"key":"1432_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186968","author":"M Oshi","year":"2020","unstructured":"Oshi M, Asaoka M, Tokumaru Y, Yan L, Matsuyama R, Ishikawa T, et al. CD8 T cell score as a prognostic biomarker for triple negative breast cancer. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21186968.","journal-title":"Int J Mol Sci"},{"key":"1432_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110569","volume":"130","author":"RR Rasmi","year":"2020","unstructured":"Rasmi RR, Sakthivel KM, Guruvayoorappan C. NF-\u03baB inhibitors in treatment and prevention of lung cancer. Biomed Pharmacother. 2020;130:110569. https:\/\/doi.org\/10.1016\/j.biopha.2020.110569.","journal-title":"Biomed Pharmacother"},{"key":"1432_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.tranon.2016.07.002","volume":"9","author":"D Ribatti","year":"2016","unstructured":"Ribatti D, Nico B, Ruggieri S, Tamma R, Simone G, Mangia A. Angiogenesis and antiangiogenesis in triple-negative breast cancer. Transl Oncol. 2016;9:453\u20137. https:\/\/doi.org\/10.1016\/j.tranon.2016.07.002.","journal-title":"Transl Oncol"},{"key":"1432_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-598","volume":"14","author":"Y Shapovalov","year":"2014","unstructured":"Shapovalov Y, Zettel M, Spielman SC, Amico-Ruvio SA, Kelly EA, Sipe GO, et al. Fluoxetine modulates breast cancer metastasis to the brain in a murine model. BMC Cancer. 2014;14:598. https:\/\/doi.org\/10.1186\/1471-2407-14-598.","journal-title":"BMC Cancer"},{"key":"1432_CR37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5487\/tr.2010.26.4.245","volume":"26","author":"H Son","year":"2010","unstructured":"Son H, Moon A. Epithelial-mesenchymal transition and cell invasion. Toxicol Res. 2010;26:245\u201352. https:\/\/doi.org\/10.5487\/tr.2010.26.4.245.","journal-title":"Toxicol Res"},{"key":"1432_CR38","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1182\/blood-2010-06-288498","volume":"117","author":"RB S\u00f8rensen","year":"2011","unstructured":"S\u00f8rensen RB, Hadrup SR, Svane IM, Hjorts\u00f8 MC, Thor Straten P, Andersen MH. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood. 2011;117:2200\u201310. https:\/\/doi.org\/10.1182\/blood-2010-06-288498.","journal-title":"Blood"},{"key":"1432_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01403-0","volume":"23","author":"J Stenstr\u00f6m","year":"2021","unstructured":"Stenstr\u00f6m J, Hedenfalk I, Hagerling C. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression. Breast Cancer Res. 2021;23:27. https:\/\/doi.org\/10.1186\/s13058-021-01403-0.","journal-title":"Breast Cancer Res"},{"key":"1432_CR40","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1093\/annonc\/mdq757","volume":"22","author":"D Tryfonopoulos","year":"2011","unstructured":"Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, McDermott EW, Evoy D, Pierce A, O\u2019Donovan N, et al. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol. 2011;22:2234\u201340. https:\/\/doi.org\/10.1093\/annonc\/mdq757.","journal-title":"Ann Oncol"},{"key":"1432_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10549-016-3928-3","volume":"159","author":"A Valachis","year":"2016","unstructured":"Valachis A, Garmo H, Weinman J, Fredriksson I, Ahlgren J, Sund M, et al. Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study. Breast Cancer Res Treat. 2016;159:293\u2013303. https:\/\/doi.org\/10.1007\/s10549-016-3928-3.","journal-title":"Breast Cancer Res Treat"},{"key":"1432_CR42","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1038\/s41380-020-00865-6","volume":"25","author":"X Wang","year":"2020","unstructured":"Wang X, Wang N, Zhong L, Wang S, Zheng Y, Yang B, Zhang J, Lin Y, Wang Z. Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients. Mol Psychiatry. 2020;25:3186\u201397. https:\/\/doi.org\/10.1038\/s41380-020-00865-6.","journal-title":"Mol Psychiatry"},{"key":"1432_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155608","volume":"129","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zeng Y, Yang W, Wang X, Jiang J. Targeting CD8(+) T cells with natural products for tumor therapy: revealing insights into the mechanisms. Phytomedicine. 2024;129:155608. https:\/\/doi.org\/10.1016\/j.phymed.2024.155608.","journal-title":"Phytomedicine"},{"key":"1432_CR44","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/pds.1719","volume":"18","author":"KJ Wernli","year":"2009","unstructured":"Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA. Antidepressant medication use and breast cancer risk. Pharmacoepidemiol Drug Saf. 2009;18:284\u201390. https:\/\/doi.org\/10.1002\/pds.1719.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1432_CR45","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.21873\/invivo.13542","volume":"38","author":"JD Yang","year":"2024","unstructured":"Yang JD, Liu YC, Wang HC, Hsu FT, Liao TL, Huang MC, Chen JH. Quetiapine significantly improves the effectiveness of radiotherapy in combating hepatocellular carcinoma progression in a Hep3B xenograft mouse model. Vivo. 2024;38:1079\u201393. https:\/\/doi.org\/10.21873\/invivo.13542.","journal-title":"Vivo"},{"key":"1432_CR46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3233\/cbm-203125","volume":"32","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Shao X, Gao C, Xu D, Wu J, Zhu X, Chen Z. High FAS expression correlates with a better prognosis and efficacy of taxanes and target regents in breast cancer. Cancer Biomark. 2021;32:207\u201319. https:\/\/doi.org\/10.3233\/cbm-203125.","journal-title":"Cancer Biomark"},{"key":"1432_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113985","volume":"157","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Chang X, Huang Y, He D. The application of antidepressant drugs in cancer treatment. Biomed Pharmacother. 2023;157:113985. https:\/\/doi.org\/10.1016\/j.biopha.2022.113985.","journal-title":"Biomed Pharmacother"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-026-01432-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01432-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-026-01432-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:34:58Z","timestamp":1774434898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-026-01432-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1432"],"URL":"https:\/\/doi.org\/10.1186\/s10020-026-01432-5","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Studies involving animal subjects\n                      The experimental mice were supplied by the National Laboratory Animal Center and approved by IACUC (CMUIACUC-2022-299, approved on February 25, 2022) at CMU. The mice were housed under a 12-hour light\/dark cycle at 25\u00a0\u00b0C in the Animal Housing Facility Center of China Medical University (Taiwan). In compliance with ethical guidelines, the maximum tumor size\/burden permitted by our ethics committee\/IRB is 2000 mm\n                      3\n                      or body weight loss over 20%. We confirm that this threshold was not exceeded throughout the study.\n                      Studies involving human subjects\n                      Open source data was used. This study was approved by the Research Ethics Committee of China Medical University Hospital, Taichung, Taiwan (CMUH110-REC1-038(CR-3)) and the Institutional Review Board of Show Chwan Memorial Hospital (SCMH_IRB No. 1140706).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors have reviewed the final manuscript and give their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}